RedHill Biopharma (RDHL) Invested Capital (2018 - 2025)

RedHill Biopharma (RDHL) has 8 years of Invested Capital data on file, last reported at $14.8 million in Q4 2025.

• On a quarterly basis, Invested Capital rose 22.92% year-over-year to $14.8 million in Q4 2025; TTM through Dec 2025 was $26.8 million, a 103.1% increase from a year earlier, with the FY2025 full-year figure at $14.8 million, up 22.92% from the prior year.
• Invested Capital for Q4 2025 stood at $14.8 million, up from $12.0 million in the prior quarter.
• Over the last five years, Invested Capital for RDHL reached as high as $83.6 million in Q4 2021 and fell as low as $1.2 million in Q4 2023.
• Historically, Invested Capital has averaged $24.5 million across 5 years, with a median of $12.0 million in 2024.
• Across the five-year window, Invested Capital slumped 89.49% in 2023 and surged 924.55% in 2024, its largest moves.
• Year by year, Invested Capital stood at $83.6 million in 2021, then plunged by 86.66% to $11.2 million in 2022, then slumped by 89.49% to $1.2 million in 2023, then jumped by 924.55% to $12.0 million in 2024, then increased by 22.92% to $14.8 million in 2025.
• Per Business Quant data, the three most recent Invested Capital figures were $14.8 million in Q4 2025, $12.0 million in Q4 2024, and $1.2 million in Q4 2023.